Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Daratumumab Plus KRd Induction and Consolidation With Tandem Transplant Has Feasibility in High-Risk Newly Diagnosed Myeloma

August 26th 2022

Induction and consolidation therapy with a combination comprised of daratumumab, carfilzomib, lenalidomide, and dexamethasone allowed 70% of patients with high-risk, newly diagnosed multiple myeloma to complete a second autologous stem cell transplant.

Isatuximab Plus Pomalidomide and Dexamethasone Shows Meaningful PFS Benefit in Multiple Myeloma

August 26th 2022

Isatuximab plus pomalidomide and dexamethasone elicited favorable progression-free survival and proved tolerable in pretreated patients with relapsed/refractory multiple myeloma.

Isatuximab-Based Regimens Demonstrate Favorable Safety in Relapsed/Refractory Multiple Myeloma

August 26th 2022

Isatuximab-containing regimens displayed favorable toxicity in patients with relapsed/refractory multiple myeloma in a real-world study.

Targeted Therapies Continue to Shift Treatment Armamentarium in Multiple Myeloma

August 26th 2022

Patient outcomes across the multiple myeloma landscape have vastly improved with the approval of multiple agents in the treatment armementarium, such as belantamab mafodotin-blmf, selinexor, and ciltacabtagene autoleucel.

Ixazomib Regimen Induces High Response Rates, Proves Tolerable in Relapsed/Refractory Multiple Myeloma

August 26th 2022

The addition of ixazomib to daratumumab, pomalidomide, and dexamethasone has elicited deep and durable response rates with a manageable safety profile as salvage therapy in patients with relapsed/refractory multiple myeloma.

Talquetamab Adverse Event Management in Myeloma Requires Early Oral, Dermatologic Interventions

August 25th 2022

Patients with multiple myeloma can mitigate the common oral and dermatologic toxicities associated with talquetamab with early intervention tactics.

Nivolumab/Ipilimumab Combo Provides Long-Term Survival Benefit in Advanced HCC After Sorafenib

August 13th 2022

The dual immunotherapy combination comprised of nivolumab given at 1 mg/kg and ipilimumab given at 3 mg/kg provided durable responses and long-term survival benefit in patients with advanced hepatocellular carcinoma following treatment with sorafenib.

Expanded Efficacy Data Underscore Nivolumab Combinations Role as Standard of Care for ESCC

August 12th 2022

Recent data highlight the value of the newly approved indications for nivolumab plus ipilimumab and nivolumab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma.

Single-Agent Pembrolizumab Maintains Survival Benefit in Sorafenib-Pretreated Advanced HCC

August 12th 2022

Pembrolizumab monotherapy continued to demonstrate durable antitumor activity with promising overall survival in patients with advanced hepatocellular carcinoma who received prior treatment with sorafenib, according to updated data from cohort 1 of the phase 2 KEYNOTE-224 trial.

Panitumumab Plus mFOLFOX6 Improves Survival in RAS Wild-Type mCRC

August 12th 2022

Treatment with frontline panitumumab and mFOLFOX6 led to a significant improvement in overall survival, plus higher response rates and R0 resection rates, compared with bevacizumab and mFOLFOX6 in patients with RAS wild-type metastatic colorectal cancer.

Targeted Agents Continue to Emerge for HER2+ GI Cancers

August 12th 2022

After HER2 was established as an actionable target in gastric cancer, its amplification has become a key biomarker of interest for other gastrointestinal cancers.

Durvalumab Plus Concurrent Radiotherapy Meets PFS End Point in Locally Advanced NSCLC

August 9th 2022

Treatment with durvalumab and concurrent radiotherapy provided a significant benefit in progression-free survival in patients with locally advanced non–small cell lung cancer, meeting the primary end point of the phase 2 DOLPHIN trial.

First-line Avelumab Elicits Numeric But Not Significant Survival Benefit Vs Chemo in Advanced PD-L1+ NSCLC

August 9th 2022

Although frontline treatment with avelumab resulted in a longer overall survival and progression-free survival than that observed with platinum-based chemotherapy in patients with advanced non–small cell lung cancer and high PD-L1 positivity, this difference did not achieve statistical significance.

Single-Agent Sunvozertinib Elicits Responses in Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations

August 9th 2022

Sunvozertinib monotherapy produced meaningful responses in patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations who received prior treatment with platinum-based chemotherapy, according to pooled data from the phase 1 WU-KONG1 and WU-KONG2 trials, plus the phase 2 WU-KONG6 trial.

Dr. Sheffield on the Economic Cost of Delaying of Treatment in NSCLC

August 9th 2022

Brandon S. Sheffield, MD, discusses the economic cost of delaying treatment while conducting biomarker testing in non–small cell lung cancer.

Dr. Levy on the Efficacy of Datopotamab Deruxtecan Plus Pembrolizumab in NSCLC

August 9th 2022

Benjamin Levy, MD, discusses the efficacy findings of the combination of datopotamab deruxtecan and pembrolizumab, with or without chemotherapy, in non–small cell lung cancer.

Boosting Lung Cancer Screening Will Improve Survival

August 9th 2022

There is an obvious way to double survival in patients with lung cancer in the next 5 years: remove barriers to screening, especially for high-risk populations.

Datopotamab Deruxtecan/Pembrolizumab With or Without Chemotherapy Elicits Responses in Advanced NSCLC

August 9th 2022

The combination of datopotamab deruxtecan and pembrolizumab, with or without platinum-based chemotherapy, displayed promising efficacy and a manageable safety profile in patients with advanced/metastatic non–small cell lung cancer.

Pembrolizumab/Etoposide Maintains Meaningful Survival Benefit in Untreated ES-SCLC

August 9th 2022

The combination of pembrolizumab and etoposide maintained benefits in overall survival (OS) and progression-free survival vs etoposide plus placebo in patients with previously untreated extensive-stage small cell lung cancer.